Compare Alcon AG (ALC) vs Royal Bank of Canada (RY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Royal Bank of Canada — how do they compare? Alcon AG trades at $66.68 (market cap $32.69B), while Royal Bank of Canada trades at $205.67 (market cap $290.60B). The key difference: Royal Bank of Canada is far larger — about 8.9× Alcon AG's market cap, and Royal Bank of Canada pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| ALC | RY | |
|---|---|---|
Market Cap | $32.69B | $290.60B |
Sector | Health | Financials |
52-Week High | $92.22 | $209.07 |
52-Week Low | $62.02 | $128.46 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Royal Bank of Canada (RY) trades at $209.07, up 2.09% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 31.85% net income margin and 17.17% ROE, supported by a $1.76 quarterly dividend and a share repurchase program. Revenue grew to $66.53B in 2025, and cash flow trends indicate improving operational strength.
RY presents a solid investment case with consistent profitability and shareholder returns, though valuation metrics like a P/E of 19.2 and P/B of 3.17 suggest premium pricing. Risks include economic sensitivity and high debt levels, but analyst consensus leans positive with 43% buy ratings. The outlook remains favorable if earnings growth persists amid macroeconomic stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
